12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zymafos palifosfamide: Phase III ongoing

Ziopharm said it expects top-line data during the last week of March after reporting that the double-blind, placebo-controlled, international Phase III PICASSO 3 trial of IV Zymafos reached the target number of PFS events required for unblinding. The trial, which completed enrollment in June, is evaluating doxorubicin with or...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >